CMS Is Tightening RPM Audits — Investors Should Pay Attention

Good morning, ! This week we unpack the explosive growth of Remote Patient Monitoring (RPM) and the massive opportunity emerging for healthcare investors. But as the market accelerates, CMS and HHS-OIG are tightening oversight with more aggressive audit standards. At the same time, healthcare’s focus is shifting from transformation to affordability as rising costs, expiring subsidies, and weak AI savings expose increasingly unsustainable economics.

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

DATA DIVE

Healthcare’s New Favorite Employee Never Sleeps

For years, Remote Patient Monitoring (RPM) sounded like one of those futuristic healthcare buzzwords destined to live forever inside conference PowerPoints. Not anymore.

The global RPM market is projected to grow from $19 billion in 2023 to $111 billion by 2033, as health systems increasingly shift from reactive care toward continuous, data-driven monitoring. In other words: healthcare is finally moving from annual checkups to “always-on” surveillance — but with fewer awkward waiting rooms.

The biggest use cases remain cardiovascular monitoring (47%) and diabetes management (31%), fueled by connected devices from players like Dexcom, Abbott, and Medtronic. Meanwhile, hospitals and insurers are embracing RPM because it helps solve a very expensive problem: keeping chronic patients out of hospitals.

The real unlock, however, may be policy. CMS reimbursement changes turned RPM from a science project into a business model, allowing providers to bill roughly $120–$150 per patient per month. Once Medicare started paying, the market stopped asking if RPM mattered and started asking how fast it could scale. (More)

HEALTHTECH CORNER

Healthcare AI Has a Trust Problem

Healthcare’s AI conversation is shifting from adoption to accountability.

According to McKinsey, the top concern among U.S. healthcare leaders is no longer implementation cost or workforce disruption. It is accuracy. 66% of executives cite inaccuracies as their primary concern with generative AI, followed by 60% pointing to security risks and 52% to regulatory and compliance exposure.

That hierarchy matters.

For the last two years, healthcare AI investment largely rewarded speed. Vendors raced to deploy copilots, ambient scribes, and workflow automation tools into clinical environments before governance frameworks fully matured. Now the market is recalibrating around reliability, auditability, and risk containment.

The implication for operators and investors is becoming clearer. Healthcare AI is moving out of its experimentation phase and into its infrastructure phase. That favors companies with clinical validation, EMR integration, security depth, and regulatory defensibility over consumer-style growth narratives.

The second-order effect may be even more important. As trust becomes the gating factor, AI adoption could consolidate around a smaller group of enterprise-grade vendors capable of assuming legal, compliance, and workflow risk at scale.

In healthcare, the next AI battleground may not be capability. It may be credibility. (More)

PRESENTED BY EXACT INSIGHT

95%+ qualified. 80%+ recontact. Built for live PE research.

When diligence moves fast, the quality of the respondent matters as much as the speed of the match.

Exact Insight helps PE teams generate more reliable primary research with 95%+ qualification rates, 80%+ recontact success, and access to vetted B2B professionals, healthcare experts, and global consumer panels. Quant, qual, and hybrid studies are built around the specific question at hand and delivered fast enough for live deal and portfolio workflows.

So whether you are pressure-testing a thesis, sizing a market, or validating a niche operator segment, you get cleaner inputs and a research process you can build on.

Scope a Diligence Project →

COMPLIANCE CORNER

Medicare Advantage Marketing Under the Enforcement Microscope

Medicare Advantage marketing has moved from a regulatory checkbox to a frontline enforcement target. CMS and HHS-OIG are expanding oversight well beyond traditional RADV audits, with increasing scrutiny on marketing practices, patient inducements, and digital outreach strategies.

The key shift is operational. CMS is scaling annual audits across all eligible contracts and deploying AI-driven analytics to identify irregular beneficiary outreach, misleading advertising, and unauthorized contact activity. Importantly, enforcement exposure now extends directly to third-party vendors, brokers, and call centers, many of which sit outside traditional compliance monitoring structures.

For payors and health systems, this materially raises enterprise risk. Incentive programs, enrollment campaigns, and digital acquisition funnels are increasingly being evaluated through a fraud and abuse lens, particularly where vulnerable Medicare populations are involved. Even relatively minor lapses around gift thresholds, marketing language, or outreach permissions can escalate into broader investigations.

The implication is clear. Marketing compliance is now an executive-level governance issue, not simply a legal review function. Organizations that lack formal vendor oversight, documented monitoring protocols, and real-time auditing capabilities may find themselves exposed to both regulatory penalties and reputational damage as enforcement accelerates. (More)

COMPETITIVE LANDSCAPE SNAPSHOT

TREND TO WATCH

Healthcare’s Affordability Reckoning Arrives

Healthcare spent the last three years chasing transformation. In 2026, the industry may be forced to confront something far less marketable: affordability.

The pressure is converging from every direction. Enhanced ACA subsidies expired, Medicaid eligibility is tightening, pharmaceutical pricing remains elevated, and providers continue absorbing rising labor, supply, and technology costs. Even AI, despite enormous investment, has yet to demonstrate consistent system-wide savings. Only 10% of health systems report significant ROI from generative AI deployment, despite widespread adoption efforts.

What changes in 2026 is visibility. Consumers are increasingly exposed to healthcare costs directly through higher premiums, narrower coverage, and out-of-pocket burden. At the same time, providers are operating with structurally weaker margins, making price compression harder to absorb.

The strategic implication is important. Affordability is no longer just a policy issue. It is becoming a competitive differentiator.

That shift is already reshaping care models. Direct-to-employer arrangements like Northwell Direct and emerging partnerships designed to bypass PBMs signal growing demand for lower-friction healthcare distribution. Meanwhile, policymakers are moving beyond transparency mandates toward active pricing intervention, including hospital rate caps and new CMMI payment models.

The next healthcare winners may not be the companies with the most advanced technology. They may be the ones that can finally prove they lower the total cost of care. (More)

"Success is not the key to happiness. Happiness is the key to success. If you love what you are doing, you will be successful."

Albert Schweitzer